After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
The company reckons its immunotherapy could improve on Keytruda.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
